Polaris Quantum Biotech is reinventing drug discovery, reducing the time it takes to find candidate molecules for drug development from the typical three years to just four months. As with other successful efforts to redesign established processes, Polaris is betting on scalability and automation. The startup, co-founded by Shahar Keinan and Bill Shipman, came out of stealth a year ago, revealing the first-ever drug discovery platform using a quantum computer, cost-efficiently scanning billions of molecules from a large chemical space. Having worked in the drug development industry for years, Polaris' founders decided to try and address the two major challenges they identified: The technology used and the business model. "We wanted to solve both of these problems together," says Polaris' CEO, Shahar Keinan.